Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jan 10;31(2):187-94.
doi: 10.1200/JCO.2011.41.2445. Epub 2012 Dec 3.

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial

Chaitanya R Divgi  1 , Robert G Uzzo, Constantine Gatsonis, Roman Bartz, Silke Treutner, Jian Qin Yu, David Chen, Jorge A Carrasquillo, Steven Larson, Paul Bevan, Paul Russo
Affiliations
Clinical Trial

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial

Chaitanya R Divgi et al. J Clin Oncol. .

Erratum in

  • Errata.
    [No authors listed] [No authors listed] J Clin Oncol. 2018 Jan 1;36(1):98. doi: 10.1200/JCO.2017.76.9950. J Clin Oncol. 2018. PMID: 29281805 Free PMC article. No abstract available.

Abstract

Purpose: A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken.

Patients and methods: This was an open-label multicenter study of iodine-124 ((124)I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection. PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous (124)I-girentuximab administration and before resection of the renal mass(es). Images were interpreted centrally by three blinded readers for each imaging modality. Tumor histology was determined by a blinded central pathologist. The primary end points-average sensitivity and specificity for clear cell renal cell carcinoma (ccRCC)-were compared between the two modalities. Agreement between and within readers was assessed.

Results: (124)I-girentuximab was well tolerated. In all, 195 patients had complete data sets (histopathologic diagnosis and PET/CT and CECT results) available. The average sensitivity was 86.2% (95% CI, 75.3% to 97.1%) for PET/CT and 75.5% (95% CI, 62.6% to 88.4%) for CECT (P = .023). The average specificity was 85.9% (95% CI, 69.4% to 99.9%) for PET/CT and 46.8% (95% CI, 18.8% to 74.7%) for CECT (P = .005). Inter-reader agreement was high (κ range, 0.87 to 0.92 for PET/CT; 0.67 to 0.76 for CECT), as was intrareader agreement (range, 87% to 100% for PET/CT; 73.7% to 91.3% for CECT).

Conclusion: This study represents (to the best of our knowledge) the first clinical validation of a molecular imaging biomarker for malignancy. (124)I-girentuximab PET/CT can accurately and noninvasively identify ccRCC, with potential utility for designing best management approaches for patients with renal masses.

Trial registration: ClinicalTrials.gov NCT00606632.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Patient flow diagram. ccRCC, clear cell renal cell carcinoma; CECT, contrast-enhanced computed tomography; IP, investigational product; PET/CT, positron emission tomography/computed tomography.
Fig 2.
Fig 2.
Patient with a 1.0-cm right renal clear cell carcinoma. (A) The mass is evident in the noncontrast computed tomography (CT) component of the positron emission tomography/computed tomography (PET/CT) scans, (B) is positive on the iodine-124 (124I) -girentuximab PET component, and (C) is clearly evident on the fused image. The mass was deemed to be positive on the contrast-enhanced CT scan of the (D) parenchymal component and (E) excretory component by Hounsfield criteria and qualitatively.
Fig 3.
Fig 3.
Patient with a 1.8-cm right renal oncocytoma. The mass was deemed to be positive for clear cell renal cell carcinoma on the contrast-enhanced computed tomography scan of the (A) parenchymal component and (B) excretory component by Hounsfield criteria and qualitatively. (C) The iodine-124 (124I) -girentuximab positron emission tomography/computed tomography scan is negative.
See this image and copyright information in PMC

Comment in

References

    1. Siegel R Ward E Brawley O , etal: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61: 212– 236,2011 - PubMed
    1. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney J Urol 170: 2163– 2172,2003 - PubMed
    1. Gill IS Aron M Gervais DA , etal: Small renal mass N Engl J Med 362: 624– 634,2010 - PubMed
    1. Klatte T Pantuck AJ Kleid MD , etal: Understanding the natural biology of kidney cancer: Implications for targeted cancer therapy Rev Urol 9: 47– 56,2007 - PMC - PubMed
    1. Kattan MW Reuter V Motzer RJ , etal: A postoperative prognostic nomogram for renal cell carcinoma J Urol 166: 63– 67,2001 - PubMed

Publication types

Associated data